AICAR Peptide 50mg (AMPK Activator)

Description

AICAR Peptide (50mg) Research Guide: AMPK Activation, Ischemia & Metabolic Pathways

AICAR (50mg)—chemically known as 5-Aminoimidazole-4-carboxamide ribonucleotide or AICA ribonucleotide—is a synthetic adenosine monophosphate (AMP) analog widely studied in cellular biology, metabolic regulation, and cardiovascular research.

Primary research interest in AICAR centers on its ability to directly stimulate AMP-activated protein kinase (AMPK). Often referred to as the cell’s “master energy sensor,” AMPK regulates metabolic homeostasis by suppressing energy-consuming anabolic processes and accelerating energy-producing catabolic pathways.

Technical Specifications & Chemical Profile

AICAR operates intracellularly by converting into its active form, ZMP (5-aminoimidazole-4-carboxamide 1-β-D-ribofuranotide), which mimics natural AMP accumulation without altering basal ATP levels.

Mechanism of Action: The AMPK Pathway

Under standard physiological conditions, cells continuously monitor their ratio of adenosine monophosphate (AMP) to adenosine triphosphate (ATP). When cellular energy is depleted—due to exercise, nutrient deprivation, or hypoxia—AMP levels rise, binding to the $\gamma$-subunit of AMPK and triggering its activation.

AICAR bypasses the need for energy depletion by entering the cell via nucleoside transporters, where adenosine kinase phosphorylates it into ZMP. ZMP acts as an AMP mimetic, binding directly to AMPK to trigger its downstream enzymatic cascades:

• Inhibition of Anabolic Pathways: Suppresses energy-draining pathways, such as fatty acid synthesis and protein translation, preserving essential ATP reserves.

• Activation of Catabolic Pathways: Accelerates glycolysis, glucose uptake, and fatty acid oxidation to replenish cellular energy.

• Mitochondrial Biogenesis: Upregulates key transcription factors like PGC-1$\alpha$, encouraging the generation of new mitochondria in skeletal muscle and hepatic tissues.

• Cellular Autophagy & Stress Response: Facilitates the clearance of damaged organelles, dampening inflammatory cascades in injured tissues.

Primary Areas of Investigation

1. Cardioprotection and Ischemia-Reperfusion Injury

Ischemia occurs when arterial blood supply to tissue is restricted, leading to severe oxygen and nutrient deficits. The subsequent restoration of blood flow (reperfusion) often paradoxically causes further cellular damage—known as ischemia-reperfusion injury—due to oxidative stress and rapid inflammation.

Research highlights AICAR’s organ-protective potential during acute cardiac events:

• Infarct Size Reduction: Meta-analyses of randomized, placebo-controlled preclinical and clinical trials demonstrate that AICAR administration significantly reduces myocardial infarction size and cardiac cell mortality.

• Anaerobic Energy Maintenance: AICAR accelerates myocardial glycogenolysis (the breakdown of stored glycogen into usable glucose) via ZMP allosteric activation of glycogen phosphorylase (GP). This provides cardiac tissue with critical substrate for anaerobic glycolysis, maintaining cellular ATP production under low-oxygen conditions.

• Vascular Function Preservation: AMPK activation by AICAR promotes endothelial nitric oxide synthase (eNOS) activation, maintaining microvascular tone and suppressing endothelial cell damage.

2. Hepatic Steatosis and Lipid Metabolism

Fatty liver disease (hepatic steatosis) is characterized by an excessive buildup of triglycerides inside hepatocytes, often driven by chronic inflammation, ethanol exposure, or metabolic dysfunction.

Preclinical trials evaluating ethanol-induced hepatic steatosis show that AICAR mitigates fatty liver changes through targeted transcription factor suppression:

• SREBP-1c Downregulation: AICAR decreases hepatic expression of Sterol Regulatory Element-Binding Protein 1c (SREBP-1c), the primary transcription factor driving liver lipid synthesis.

• Fatty Acid Synthase (FAS) Suppression: Downstream of SREBP-1c reduction, expression of the key enzyme Fatty Acid Synthase (FAS)—which converts acetyl-CoA and malonyl-CoA into long-chain saturated fatty acids like palmitate—is significantly reduced.

• Triglyceride Reduction: The dual suppression of SREBP-1c and FAS leads to a marked drop in hepatic triglyceride accumulation and tissue inflammation.

3. Muscle Metabolism, Glucose Transport, and Physical Endurance

In skeletal muscle models, AICAR induces metabolic adaptations reminiscent of endurance exercise without requiring physical exertion.

• Insulin-Independent Glucose Uptake: AICAR promotes the translocation of Glucose Transporter 4 (GLUT4) storage vesicles to the cell membrane, enhancing glucose entry into muscle tissue independently of insulin.

• Enhanced Insulin Sensitivity: By lowering intramuscular lipid intermediates (e.g., diacylglycerol and ceramides), AICAR reverses lipid-induced insulin resistance in metabolic models.

• Endurance Gene Profiles: Chronic administration of AICAR upregulates endurance-related gene expression, boosting oxidative capacity, slow-twitch muscle fiber conversion, and overall physical stamina in experimental subjects.

Comparative Matrix: AICAR vs. Related Research Peptides & Compounds

When structuring research protocols on metabolic modulation, cell survival, or tissue repair, researchers frequently compare AICAR against other peptide candidates:

Frequently Asked Questions (FAQ)

What is the primary function of AICAR in laboratory research?

AICAR acts as a potent, cell-permeable activator of AMP-activated protein kinase (AMPK). It is primarily used to investigate energy balance pathways, glucose uptake in skeletal muscle, tissue resistance to ischemia, and suppression of lipid synthesis.

How does AICAR differ from traditional growth hormone secretagogues?

Unlike growth hormone secretagogues (e.g., CJC-1295 or GHRP-2) that work via endocrine signaling pathways, AICAR directly modifies intracellular energy sensing at the enzymatic level by converting into ZMP and activating AMPK directly within target cells.

What is ZMP, and why is it crucial to AICAR’s function?

ZMP (5-aminoimidazole-4-carboxamide 1-β-D-ribofuranotide) is the active intracellular derivative of AICAR. Once AICAR crosses the cell membrane, it is phosphorylated into ZMP, which structural studies confirm binds directly to the AMP-binding site on the $\gamma$-subunit of AMPK.

What storage conditions are required for AICAR 50mg?

Lyophilized AICAR powder should be kept in a cool, dry place away from direct light, ideally at -20°C for long-term storage. Once reconstituted with sterile or bacteriostatic water, the solution should be kept refrigerated at 2°C–8°C and used within the recommended experimental timeframe to prevent peptide degradation.